Skip to content Skip to sidebar Skip to footer

Newsletter

Technology

Airwallex: Will this Australian-born fintech IPO in 2026? There were high hopes, but these may have been dashed

Investors speculate about which private companies could IPO and Airwallex has been one of the most commonly mentioned names. The decade-old fintech completed two US$300m funding rounds during 2025 with the latter valuing it at US$8bn (A$12bn). Although it does not have to disclose its full financials as a private company, the company has indicated that…

ByNick SundichJanuary 23, 2026

Amaero (ASX:3DA) Where US Reshoring Meets High-Value Metal Powders

Critical Metals, Defence Demand and a US-Focused Growth Story For investors looking to uncover opportunities in structurally growing sectors, the reshoring of US manufacturing and the push to secure critical mineral supply chains continue to create meaningful tailwinds. Amaero (ASX:3DA) is emerging as a supplier of high value refractory spherical metal powders, including titanium alloys…

ByCharlie YouldenJanuary 22, 2026

Metal Powder Works (ASX:MPW) Strong Commercial Demand Beneath a Noisy Market Reaction

Volumes Surge, Customers Grow, Scale Is the Next Test At a commercial and operational level, and despite the market reaction, we view this as a strong quarterly performance for Metal Powder Works. Customer engagement continued to accelerate, and copper and titanium powder volumes increased by more than 300% as multi-alloy customer programs expanded. In addition,…

ByCharlie YouldenJanuary 21, 2026

Paladin Energy (ASX:PDN) Higher Grades Drive a Strong Quarter

Why the Market Re-Rated This Uranium Update Despite broader market volatility, Paladin delivered a strong operational result, with the share price rising around 10% following the quarterly update. In our view, the move reflects improving execution and growing confidence in the company’s production profile. During the quarter, Paladin produced 1.23 million pounds of uranium and sold…

ByCharlie YouldenJanuary 21, 2026

Metallium (ASX:MTM) A$75m Raise Funds the Leap to US Commercial Scale

Funding in Place for the Next Phase of US Expansion Metallium has completed a A$75 million capital raising at A$0.84 per share, led by US-based institutional investors. The placement resulted in the issuance of approximately 89 million new shares and provides the company with the balance sheet strength needed to accelerate its next phase of…

ByCharlie YouldenJanuary 21, 2026

Qoria (ASX:QOR) A 25% Sell-Off Despite Ongoing Growth (What Happened?)

ARR Grew, Sentiment Fell Qoria (ASX: QOR) delivered what we would describe as a reasonably solid quarterly result, yet the market reaction told a very different story. The share price fell around 25% on the day, which tells us expectations were clearly set higher. In this note, we want to unpack what actually happened in…

ByCharlie YouldenJanuary 20, 2026

Nanoveu (ASX:NVU) A$7.5m Raise Funds the Next Phase Of Drone Chips

Funding the Next Chapter of Growth, Not Plugging Holes Nanoveu (ASX:NVU) has raised A$7.5 million through an upsized strategic placement to new and existing institutional investors at A$0.088 per share. From an investor perspective, this capital raise is best viewed as funding for the company’s next phase of execution rather than a balance sheet repair. Importantly,…

ByCharlie YouldenJanuary 20, 2026

Telix Pharmaceuticals (ASX:TLX) China Regulatory Progress Emerges After a 55% Sell-Off

The China Regulatory Path Is Still Moving Forward Telix Pharmaceuticals (ASX:TLX) has had a challenging start to the year, with the share price down around 55% and now trading near A$11.70 at the time of writing. In our experience, this is often when a stock becomes worth revisiting. Sustained share price weakness can create opportunities,…

ByCharlie YouldenJanuary 20, 2026

Novonix (ASX:NVX) Big Customers, Slipping Timelines, and a Market Losing Patience

The Cost of Optimistic Timelines in Battery Manufacturing Novonix has experienced a volatile year, with the share price ranging from highs near A$1.00 to more recent levels around A$0.42. That decline reflects a series of setbacks that have weighed on investor confidence in Novonix and reshaped the near term growth narrative. Around November, the company lost…

ByCharlie YouldenJanuary 19, 2026

4DMedical (ASX:4DX) What the Market Is Really Pricing In at A$5.40

What Retail Investors Need to Know Before Chasing the Story 4DMedical has quickly become one of the more talked about stocks in the market, and with that attention comes the need for clarity. In this piece, we want to break down the company’s latest investor presentation and what it really means for shareholders. That includes a…

ByCharlie YouldenJanuary 19, 2026